This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Anaemia associated with Chronic Kidney Disease
  • /
  • A Study of Efepoetin Alfa in Treating Anaemia Asso...
Clinical trial

A Study of Efepoetin Alfa in Treating Anaemia Associated With Chronic Kidney Diseases Patient

Read time: 1 mins
Last updated:19th Nov 2020
Status: Recruiting
Identifier: NCT04155125
A Study of Efepoetin Alfa in Treating Anaemia Associated With Chronic Kidney Diseases Patient

Brief Summary:

This is an open-label, randomised, multicenter, Mircera-controlled, parallel-group, Phase III study to determine whether subcutaneous administered efepoetin alfa is as effective and well tolerated as subcutaneous Mircera for anaemia correction and maintenance in erythropoiesis stimulating agent (ESA)-naïve subjects who have CKD and are not on dialysis. ESA prior users who have stopped using ESA at least 12 weeks till screening will also be eligible for this study provided they fulfil all the subject entry criteria.

Detailed Description:
The study will consist of a 20-week correction period for dosage titration and Hb correction, followed by an 8-week evaluation period for efficacy assessments of corrective treatment. Subjects who respond to efepoetin alfa (defined as an increase in Hb ≥1.0 g/dL versus baseline and Hb level within 10 - 12 g/dL range without blood transfusion during the 28 weeks after the first dose) will be eligible to continue treatment, and will be randomised to receive subcutaneous efepoetin alfa either once every 2W or every 4W for an additional 24-week extension period to assess long-term safety and maintenance effect. Mircera responders will also be allowed to continue the drug during the extension period, receiving it every 4 weeks using the dose equal to twice the previous once-every-two-week dose. The safety data collected will be part of an ongoing pooled analysis of safety data from the efepoetin alfa clinical development program.

Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 386 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-Label Randomised Controlled Trial of Efepoetin Alfa for Treatment of Anaemia Associated With Chronic Kidney Disease Patients Not on Dialysis (ND-CKD). A Non- Inferiority Trial Compared to Methoxy Polyethylene Glycol-Epoetin Beta (MIRCERA)
Actual Study Start Date: July 2, 2020
Estimated Primary Completion Date: December 31, 2021
Estimated Study Completion Date: June 30, 2022

- Experimental: efepoetin alfa
- Placebo Comparator: Mircera

Category Value
Study type(s) Interventional
Estimated enrolment 386
Actual Study start date 02 July 2020
Estimated Study Completion Date 30 June 2022

View full details